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Background: As alcohol-related health problems continue to rise, the attention of policy-makers is increasingly
turning to Screening and Brief Intervention (SBI) programmes. The effectiveness of such programmes in primary
healthcare is well evidenced, but very few cost-effectiveness analyses have been conducted and none which
specifically consider the Italian context.
Methods: The Sheffield Alcohol Policy Model has been used to model the cost-effectiveness of government
pricing and public health policies in several countries including England. This study adapts the model using Italian
data to evaluate a programme of screening and brief interventions in Italy. Results are reported as Incremental
Cost-Effectiveness Ratios (ICERs) of SBI programmes versus a ‘do-nothing’ scenario.
Results: Model results show such programmes to be highly cost-effective, with estimated ICERs of €550/Quality
Adjusted Life Year (QALY) gained for a programme of SBI at next GP registration and €590/QALY for SBI at next GP
consultation. A range of sensitivity analyses suggest these results are robust under all but the most pessimistic
assumptions.
Conclusions: This study provides strong support for the promotion of a policy of screening and brief interventions
throughout Italy, although policy makers should be aware of the resource implications of different implementation
options.
Keywords: Public health interventions, Alcohol, Primary care, Cost-effectivenessBackground
The negative health and social impacts of excessive alco-
hol consumption are well-documented and place a heavy
cost-burden on society [1]. Drinking has been identified
as a contributory factor in a wide range of health condi-
tions [2] and as a high priority cause of chronic disease
in Italy [3]. As a result, the attention of policymakers is
increasingly turning to screening and brief intervention
(SBI) programmes. The recent World Health Organisa-
tion (WHO) European Action Plan to Reduce the Harm-
ful Use of Alcohol [4] recommends such programmes as
a key strategy for health services throughout the* Correspondence: c.r.angus@sheffield.ac.uk
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unless otherwise stated.continent and the use of SBIs in primary care is cur-
rently recommended in Italian national guidelines [5].
However, whilst the effectiveness of SBI in reducing alco-
hol consumption is well-evidenced [6-8], recent systematic
reviews of cost-effectiveness literature [9,10] have identi-
fied few studies into the cost-savings resulting from SBI
programmes, none of which which focus on the Italian
context. This lack of evidence may be acting as a signifi-
cant barrier to the wider implementation of SBIs by the
regional bodies in Italy responsible for public health.
This study forms part of the European Commission
funded Optimising Delivery of Healthcare Interventions
(ODHIN) project, which uses SBI in primary healthcare
as a case study to investigate how primary healthcare
professionals can be encouraged to implement practices
which clinical research shows to be effective. RecentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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healthcare to be highly cost-effective in England [11]
and this study adapts this work using Italian data to esti-
mate the cost-effectiveness of SBI programmes in pri-
mary healthcare in Italy.
Our analysis evaluates two alternative SBI policies. We
considered the uncertainty around the existing evidence
by examining a range of sensitivity analyses, as well
as investigating the impact of using alternative
screening tools. Our results are then compared with
those of recent cost-effectiveness studies in other
countries.Figure 1 High-level conceptual framework for the model.Methods
Model structure
We adapted an existing alcohol policy appraisal model -
the Sheffield Alcohol Policy Model - which has been used
to evaluate pricing policies in England and Scotland
[12-14] and screening and brief intervention policies in
England [15]. This model takes existing alcohol con-
sumption in the population and estimates how this
changes over time as the result of an intervention. These
changes are then used to estimate the impact on popula-
tion health. The high-level conceptual framework of the
model is shown in Figure 1.
We modelled a 10 year programme of screening and
brief interventions in primary healthcare with a 30 year
time horizon to allow the full impact on health outcomes
to be considered. The model utilises an adapted form of
Gunning-Scheper’s method of potential impact fractions
and alcohol-attributable fractions (AAFs) [16] to estimate
the change in mortality and morbidity rates resulting from
changes in consumption (see pages 25–36 of Purshouse
et al. [15] for full details). These rates are used to adjust
the population life tables and obtain revised levels of mor-
tality and morbidity for a range of health conditions,
which can then be compared to a no intervention sce-
nario. Health outcomes are calculated on a population
subgroup level, with subgroups defined by age (16–17,
18–24, 25–34, 35–44, 45–54, 55–64, 75+), sex and mean
alcohol consumption at baseline (measured in grams of
pure ethanol/week).
Screening is modelled by constructing a screening ar-
rival profile which represents the proportion of each age
and gender subgroup being screened in each year of the
10 year programme. Each individual in the population,
represented in the model by an individual survey respond-
ent, can be screened no more than once and it is assumed
that all individuals are screened at the first opportunity.
The actual samples in each subgroup selected for screen-
ing in each year are chosen randomly, accounting for sam-
ple weights. A more in-depth explanation of the full
modelling methodology can be found elsewhere [11,15].The perspective for this analysis is that of the na-
tional healthcare system, including cost savings to the
Italian National Health Service (INHS) as a result of
reduced morbidity and improvements in health-related
quality of life for drinkers as well as the direct costs
of illness and the opportunity costs of delivering the
SBIs in primary care. All costs and health outcomes
are discounted at a rate of 3%, with values of 0% and
5% tested as sensitivity analyses in line with current
Italian guidance [17], and all costs are presented in
2008 prices.Italian model parameters
Consumption data
We obtained consumption data for the Italian popula-
tion from the Aspects of Daily Life survey 2008 [18,19],
conducted by the Italian national statistics institute
(ISTAT). This nationally representative survey (N =
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well as asking a series of quantity-frequency questions re-
garding their usual alcohol consumption. These responses
were converted to a mean weekly consumption in grams
of alcohol. The survey also asks respondents how many
times in the preceding year they have drunk 6 or more
glasses of alcoholic beverage (1 glass = 12 grams of pure
alcohol). We used this as a measure of the risk of harm
for health conditions associated with acute, rather than
chronic, alcohol consumption.
Mortality and morbidity data
We modelled 42 alcohol-attributable health conditions
based on the work of the WHO on the global burden of
disease due to alcohol [20,21] (see Table 1). Absolute
mortality data from 2008 for the 42 health conditions
was obtained from ISTAT for each age and gender
subgroup in the model. Morbidity data was derived
from the Italian database of hospital admissions for
2008, which contained a total of 1,559,310 admissions
for the 42 alcohol-related health conditions. In order
to account for repeat admissions in the same year for
the same individual, the absolute number of admis-
sions was divided by the adjustment coefficients shown
in Table 1. These coefficients were calculated from
hospital admissions data for the Netherlands as no
Italian data was available and were obtained from the
Dutch Hospital Data Foundation (DHD) [22]. UK co-
efficients were used in previous versions of the Shef-
field Model [15], however these were estimated
indirectly from several data sources, whereas the DHD
data allowed them to be calculated directly. The co-
efficients represent the mean number of admissions
in a year for an individual with each health condition
and full details on their derivation are contained
within the Additional file 1. Hospital admissions data for
Italy was not available for any of the partially-attributable
acute conditions, so these were estimated from UK mor-
bidity data using the relationship between Italian and UK
mortality rates for each relevant condition.
Consumption-risk relationships
Risk functions relating alcohol consumption (either mean
consumption level or frequency of acute drinking) to risk
are required to implement the potential impact fraction
method. Following a recent review by the Sheffield
Alcohol Research Group, updated risk functions were
identified for malignant neoplasm of the lip, oral cavity
and pharynx [23], malignant neoplasm of the liver and
intrahepatic bile ducts [24], malignant neoplasm of the lar-
ynx [25], malignant neoplasm of the breast [26], epilepsy
[27] and cardiac arrhythmias [28]. For all other partially-
attributable chronic conditions the same risk functions as
have been implemented previously [29] were used. Forpartially attributable acute conditions (e.g. falls and as-
saults) we used Italy-specific alcohol-attributable frac-
tions [19] where available, or otherwise those from
England [30], and assumed a linear relationship between
frequency of drinking >6 glasses and risk to calculate
risk functions for each age-gender subgroup. For wholly-
attributable partial and chronic conditions, the risk
functions were calibrated to the actual absolute levels of
morbidity and mortality in the population, assuming a linear
relationship between alcohol consumption/binge frequency
and risk. Further details of the calibration methodology and
risk functions used are included in the Additional file 1.
Healthcare costs of alcohol-attributable health conditions
The model incorporates all healthcare costs to the INHS
for each health condition, including inpatient, outpatient
and accident and emergency visits, ambulance costs, GP
consultations, nurse visits and other costs. For each cost
category identified, we aimed to collect context-specific
costs in line with the study perspective. In Italy, hospitals
are funded through reimbursement tariffs that vary across
21 regions and between different types of providers. The
reimbursement tariffs are estimated on the basis of full
cost of hospitalisation and are inclusive of all inpatient
services in addition to emergency visits if these led to hos-
pitalisation [31]. Since we aimed to obtain nationally rep-
resentative estimates, we assigned hospital costs to each
admission in the database based on the nationally defined
reimbursement tariff which applies when a patient is
treated outside their region of residence. Out of 42 identi-
fied alcohol-attributable conditions, Italian data were
available for 33. Mean costs were calculated for each con-
dition by gender and tested for significant differences be-
tween sexes using student t-tests in Stata 11 [32]. Costs
were significantly different (p < 0.01 in all cases) for 11 of
the conditions for which data was available. Where there
was no significant difference (p > 0.23 in all cases) the
overall population mean was used. For conditions where
no cost data was available in Italy, English costs [15] were
adjusted by the mean ratio between Italian and English
costs for all other conditions. This assumption was tested
with a sensitivity analysis assuming, conservatively, that
these costs were 25% lower than the baseline estimates.
Costs not covered within the hospital reimbursement tar-
iffs (e.g. ambulance and GP costs) were estimated assum-
ing the ratio of hospital admission to other costs for each
condition was the same as in England.
Costs of screening and brief intervention
The costs associated with implementing a screening and
brief intervention programme were separated into the
cost of briefing materials provided to the patient and the
cost of the GP’s time. The former were taken from a UK
study by Lock et al. [33], converted into euros using
Table 1 Alcohol-attributable health conditions included in the model
Health condition ICD-10 code(s) Total
mortalities
(2008)
Hospital
admissions
(2008)
Adjustment
coefficient
Estimated
morbidity
(2008)
Wholly alcohol-attributable chronic conditions
Alcohol-induced pseudo-Cushing's syndrome E24.4 0 774 1.17 661
Degeneration G31.2 29 284 1.10 257
Alcoholic polyneuropathy G62.1 12 444 1.14 390
Alcoholic myopathy G72.1 0 99 1.00 99
Alcoholic cardiomyopathy I42.6 15 99 1.26 79
Alcoholic gastritis K29.2 1 104 1.09 96
Alcoholic liver disease K70 10 3283 1.51 2179
Chronic pancreatitis K86.0 7 17901 1.47 12180
Wholly alcohol-attributable acute conditions
Excessive blood level of alcohol R78.0 0 16 1.00 16
Mental and behavioural disorders
due to use of alcohol
F10 236 13930 1.14 12242
Ethanol poisoning T51.0 2 112 1.11 101
Methanol poisoning T51.1 0 3 1.00 3
Toxic effect of alcohol, unspecified T51.9 8 16 1.22 13
Accidental poisoning by exposure to alcohol X45 0 0 1.03 0
Partially alcohol-attributable chronic conditions
Malignant neoplasm of lip, oral cavity and
pharynx
C00-C14 2742 10467 1.59 6580
Malignant neoplasm of oesophagus C15 1773 4340 2.19 1982
Malignant neoplasm of colon and rectum C18-21 18471 68903 2.14 32157
Malignant neoplasm of liver and intrahepatic
bile ducts
C22 9429 30738 1.59 19322
Malignant neoplasm of larynx C32 1707 9046 1.47 6173
Malignant neoplasm of breast C50 12298 69691 2.35 29605
Diabetes mellitus (typeII) E10-E14 20170 110599 1.31 84107
Epilepsy and status epilepticus G40-G41 659 31738 1.16 27276
Hypertensive diseases I10-I15 21315 117558 1.19 99091
Ischaemic heart disease I20-I25 75044 350551 1.19 294472
Cardiac arrhythmias I47-I49 7806 168777 1.27 132619
Haemorrhagic stroke I60-I62 10611 34635 1.07 32320
Ischaemic stroke I63 1974 260020 1.07 243881
Oesophageal varices I85 67 2300 1.50 1534
Unspecified liver disease K74 6986 60244 1.32 45709
Cholelithiasis K80 629 137456 1.16 118453
Acute and chronic pancreatitis K85, K86.1 1052 10711 1.10 9708
Psoriasis L40 excl. L40.5 23 17017 5.74 2966
Spontaneous abortion O03 0 32258 1.05 30616
Partially alcohol-attributable acute conditions
Motor vehicle accidents V0-V04, V06, V09-V80, V87, V89, V99 4712 N/A 1.05 40280
Fall injuries W00-W19 2910 N/A 1.05 278333
Drowning W65-W74 312 N/A 1.00 212
Fire injuries X00-X09 212 N/A 1.12 2080
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Table 1 Alcohol-attributable health conditions included in the model (Continued)
Health condition ICD-10 code(s) Total
mortalities
(2008)
Hospital
admissions
(2008)
Adjustment
coefficient
Estimated
morbidity
(2008)
Accidental poisoning by exposure to noxious
substances
X40-X49 468 N/A 1.03 3723
Other unintentional Injuries V05, V07, V08, V81-V86, V88, V90-V98, W20-W64,
W75-W99, X10-X39, X50-X59, Y40, Y86, Y88, Y89
10392 N/A 1.06 26458
Intentional self-harm X60-X84, Y87.0 3794 N/A 1.15 35440
Assault X85-Y09, Y87.1 427 N/A 1.04 42681
Other intentional injuries Y35 0 N/A 1.10 505
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prices using the consumer prices index for Italy [35]. To
obtain an estimate of the GP’s time, we first estimated the
annual salaries of GPs of different levels of seniority, using
data from the Friuli-Venezia-Giulia (FVG) region of Italy.
We took an average of these, weighted by the proportion
of GPs at each level in the province of Udine (in the FVG
region) to give us an estimate for the mean annual salary
of a GP of €79900 before tax. Italian GPs spend an average
of 15 hours contact time in surgery with patients [36] and
an estimated 12.5 hours on home visits, giving us an aver-
age direct cost per minute to the INHS of €0.87 for this
contact time (after adjusting to 2008 prices). As no data
exists on the costs of overheads and other related costs
(such as ongoing training) these were estimated relatively
from UK figures [37], giving a total cost per minute to the
INHS of €1.07. Owing to the uncertainty around this
figure, an alternative estimate of €1.58, derived using the
absolute UK costs, was used as a sensitivity analysis.
Screening coverage
Two alternative intervention settings were examined: the
screening of patients when they next registered with a new
GP and screening when they have their next standard GP
consultation. Data on between-GP migration by patient age
and gender was obtained for the Friuli-Venezia-Giulia re-
gion for a 10 year period from 2000–2009 (personal com-
munication from Roberto Maffetone at INSIEL) together
with regional population demographics for the same period
from ISTAT. These were used to derive a gender and age-
group specific ‘arrival profile’, after adjusting for long-term
trends in migration, giving the probability of being screened
in each year of a 10 year screening programme, assuming
that the probability of registering with a new GP was inde-
pendent from year to year. Data on the mean frequency of
GP consultations by age and gender was obtained for both
Italy [38] and England [39] and used to estimate the pro-
portion of patients in each subgroup who would visit their
GP in each year of the programme. Full details of the met-
hodology used in this estimation are given in an additional
file [Additional file 1].In line with current Italian guidelines, screening is mo-
delled using the AUDIT-C questionnaire with a threshold
of 4 for women and 5 for men [40] with a brief inter-
vention lasting 10 minutes for all patients who screen
positive. The probability of a patient screening positively,
given their alcohol consumption, was estimated using
screening models derived from the UK Psychiatric
Morbidity Surveys from 2000 and 2007. Evidence on
the relationship between duration of intervention and
effectiveness is inconclusive [7] and therefore the mean ef-
fect estimate of a 12.3% reduction in consumption after a
24.9 minute intervention, taken from the Cochrane review
of Kaner et al. [6], is applied to all patients who receive
the intervention. This reduction is assumed to rebound
linearly towards the patient’s baseline consumption over
a period of 7 years in line with the findings of Fleming
et al. [41].
In order to investigate the impact of uncertainty around
the hospital costs estimated indirectly from UK costs, the
cost of GP’s time, the duration and magnitude of effect of
the intervention on patients’ drinking and the relationship
between these and the duration of the brief intervention it-
self, we conducted a number of sensitivity analyses using
more pessimistic assumptions for these parameters. A num-
ber of alternative scenarios were also examined to explore the
estimated impact of using different screening tools, such as
the full AUDIT questionnaire, FAST, which has been recom-
mended for use in primary care [42], or combinations of se-
veral tools (e.g. full AUDIT with an AUDIT-C pre-screen).
Results
Population coverage
The population coverage for a programme of screening at
next GP registration is estimated to be 63% of the total
adult population, leading to 32% of people receiving a
brief intervention during the 10 years of the programme.
Coverage is spread relatively evenly across the 10 years,
peaking in year 1 with 11% of the population being
screened. A programme of screening at next consultation
is estimated to capture 97% of the population over 10
years, with 49% of adults receiving an intervention as a
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the programme, with 84%% of people being screened in
the first year. Figure 2 shows these coverage profiles over
the lifetime of the programme.
Screening at next GP registration
Over the course of 30 years, a programme of screening at
next GP registration is estimated to result in 7200 fewer
alcohol-attributable deaths, predominantly amongst men
(66%) and from chronic (68%), rather than acute causes.
The total number of hospitalisations saved by the
programme is estimated to be 91700, also largely amongst
men (72%) and for chronic conditions (67%). Table 2 gives
a detailed breakdown of the estimated impact on alcohol-
related morbidity in the fifth year of the programme.
The cost of delivering SBIs over the 10 year programme
is estimated to be €411 million. This is offset by a total re-
duction in hospital costs over 30 years of €370 million. The
total gain in Quality-Adjusted Life Years (QALYs) is esti-
mated to be 75200 giving an Incremental Cost-Effectiveness
Ratio (ICER) of €550/QALY, suggesting that such a
programme is close to being cost-neutral. As a large propor-
tion of the health benefits are experienced by men (69% of
total QALYs), delivering SBIs to men only is estimated to be
cost-saving, although the estimated ICER for a female-only
SBI programme of €3100/QALY is still well within the re-
commended Italian threshold of €25000-€40000/QALY [43].
Screening at next GP consultation
As a programme of SBI at next GP consultation has a
wider coverage, it is estimated to produce even greater im-
provements in public health, with 12400 fewer alcohol-
attributable deaths and 153700 fewer hospital admissions
over 30 years. The cost of delivery is also higher, at €687
million, although this is offset by cumulative healthcare
savings of €605 million, making the programme around0%
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Figure 2 Population coverage of modelled screening programmes.twice as expensive as screening at next registration. Health
savings are estimated to be 139200 additional QALYs, gi-
ving an ICER of €590/QALY and suggesting there is little
to choose between the two programmes in terms of cost-
effectiveness. It should be noted that as the majority of
SBIs take place in the first year of the programme, the bulk
of the delivery costs are incurred up front, whilst the
healthcare savings are accrued over a longer time frame.
This is in contrast to screening at next registration, where
the SBI costs are spread more evenly across the duration
of the programme. Figure 3 shows the cumulative net
costs of both programmes over time.
Sensitivity analyses - discount rate
In order to investigate the sensitivity of model results
around the baseline Italian discount rate of 3%, guide-
lines recommend alternative rates of 0% and 5% being
tested. For a programme of screening at next registration
a rate of 0% makes the programme cost-saving, whilst
5% increases the estimated ICER to €1200/QALY. For
screening at next consultation similarly small effects are
observed with 0% and 5% leading to estimates of €60
and €1100/QALY respectively.
Sensitivity analyses - model assumptions
Whilst the assumptions in the base case scenarios are
the best representation of the available evidence, a range
of further analyses have been performed using more pes-
simistic assumptions around the size of effect and du-
ration of effect of the intervention as well as the length
of the intervention and the staff costs of the GPs deliver-
ing the SBIs. Results of these analyses are presented in
Table 3, showing that even under the most pessimistic of
assumptions is it likely that either programme would
be considered cost-effective under current Italian
guidelines [43].7 8 9 Never
rogramme
Next Registraion
Next Consultation
Table 2 Estimated reductions in morbidity (absolute and relative to baseline) in the 5th year of a programme of SBI for patients being screened at their next
GP registration
16-24 years 25-44 years 45-64 years 65 years or older Total
M F M F M F M F M F All
Condition N % N % N % N % N % N % N % N % N % N % N %
Alcoholic poisoning 0 −1.7% 0 −3.1% −1 −3.1% 0 −4.9% −1 −4.0% −2 −12.2% −1 −6.5% 0 −2.4% −2 −3.5% −2 −6.4% −4 −4.6%
Alcoholic disorders −12 −2.2% −9 −2.8% −204 −3.3% −93 −4.0% −259 −3.3% −182 −5.5% −132 −2.9% −104 −2.6% −608 −3.2% −388 −3.9% −996 −3.4%
Assault −59 −0.4% −16 −1.0% −199 −1.1% −52 −2.0% −73 −1.7% −13 −1.9% −17 −2.3% −4 −0.8% −348 −0.9% −84 −1.6% −432 −1.0%
Road traffic accidents −92 −1.2% −10 −0.5% −151 −1.2% −16 −0.5% −52 −0.9% −8 −0.4% −23 −0.8% −9 −0.4% −318 −1.1% −44 −0.4% −362 −0.9%
Epilepsy −30 −1.4% −2 −0.1% −46 −1.5% −3 −0.1% −29 −0.9% −6 −0.3% −29 −0.8% −5 −0.1% −134 −1.1% −16 −0.1% −150 −0.6%
Other accidents −37 −0.3% −12 −0.3% −217 −0.8% −74 −0.7% −232 −1.0% −129 −0.8% −894 −1.3%
%
−168 −0.1% −1380 −1.1% −382 −0.2% −1762 −0.6%
Intentional self harm −6 −0.2% −18 −0.3% −36 −0.5% −64 −0.7% −20 −0.7% −25 −0.7% −12 −1.0% −5 −0.3% −74 −0.5% −112 −0.6% −186 −0.5%
Diseases of the digestive
system
−5 −0.5% 1 0.0% −82 −0.6% 6 0.0% −145 −0.5% 2 0.0% −102 −0.3% −27 −0.1% −334 −0.4% −19 0.0% −353 −0.2%
Diseases of the circulatory
system
−27 −1.3% −1 −0.1% −82 −0.4% −11 −0.1% −578 −0.4% −218 −0.3% −398 −0.1% −211 −0.1% −1085 −0.2% −440 −0.1% −1525 −0.2%
Neoplasms 0 −0.2% 0 −0.1% −3 −0.3% −5 −0.1% −52 −0.3% −14 −0.1% −16 0.0% −11 0.0% −71 −0.1% −30 0.0% −101 −0.1%
Other −1 −0.3% 0 0.0% −6 −0.4% −2 0.0% −5 −0.2% −2 −0.1% −2 −0.2% −1 −0.1% −14 −0.3% −4 0.0% −18 0.0%
Diabetes 3 0.1% 0 0.0% 11 0.2% 1 0.0% 28 0.2% 2 0.0% 27 0.1% 3 0.0% 69 0.2% 7 0.0% 76 0.1%
Total −266 −0.6% −66 −0.3% −1016 −0.8% −312 −0.3% −1418 −0.5% −596 −0.4% −1599 −0.3% −540 −0.1% −4299 −0.5% −1514 −0.2% −5813 −0.3%
Included ICD-10 codes: (1) T51.0, T51.1, T51.9, X45; (2) E24.4, R78.0, F10, G31.2, G62.1, G72.1, I42.6, K29.2, K70, K86.0; (3) X85-Y09, Y87.1; (4) V0-V04, V06, V09-V80, V87, V89, V99; (5) G40-G41; (6) W00-W19, W65-W74,
X00-X49, V05, V07, V08, V81-V86, V88, V90-V98, W20-W64, W75-W99, X10-X39, X50-X59, Y40, Y86, Y88, Y89; (7) X60-X84, Y87.0; (8) I10-I15, I20-I25, I47-I49, I60-I63; (9) I85, K74, K80, K85, K86.1; (10) C00-C15, C18-22, C32,
C50; (11) L40 excl. L40.5, O03, Y35 (12) E10-E14.
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Figure 3 Cumulative net costs of modelled screening programmes (implementation costs and cost-savings to INHS).
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Table 4 presents the results of a range of alternative
model runs, showing the estimated impact of using al-
ternative screening tools and thresholds. These results
show that whilst the current recommended screening
tool in Italy (AUDIT-C 5/4) is the most expensive to im-
plement, it is also the most effective and produces the
greatest net benefit for both screening at next registra-
tion and at next consultation. The results also illustrate
the scale of potential net benefits from adopting a na-
tional SBI policy (estimated to be in excess of €1.3 bn at
a willingness-to-pay threshold of €25000/QALY for any
of the modelled scenarios).
Discussion
This adaptation of SAPM provides the first cost-
effectiveness analysis of screening and brief intervention
programmes in Italy, examining two implementation op-
tions: screening at the next registration with a new GPTable 3 Impact of pessimistic alternative assumptions for SBI
‘do-nothing’ scenario
Next registration Base case Lower hospital costs
(−25% for estimated
values)
Base case € 550 € 1000
Less effective (5.9% reduction) € 3600 € 4100
Shorter effect (3 year rebound) € 7500 € 8000
Less effective & shorter effect
(5.9% reduction & 3 year rebound)
€ 14300 € 14800
Next consultation Base case Lower hospital costs
(−25% for estimated
values)
Base case € 590 € 950
Less effective (5.9% reduction) € 2500 € 3700
Shorter effect (3 year rebound) € 5900 € 7400
Less effective & shorter effect
(5.9% reduction & 3 year rebound)
€ 11600 € 13600or screening at the next GP consultation. The outcome
measures observed were the costs of screening, the re-
duction in costs to the INHS as a result of reduced mor-
bidity and mortality and the improvement in health
outcomes measured in QALYs, in line with standard
practice in Italian cost-effectiveness analyses [17]. The
resulting incremental cost-effectiveness ratios for all sce-
narios suggest that either of the modelled SBI pro-
grammes would be highly cost-effective when compared
with a policy of no SBI, under current Italian guidelines
[43], with a policy of SBI at next consultation using the
current AUDIT-C 5/4 screening tool bringing the great-
est net benefit of all modelled options (at a willingness-
to-pay threshold of €25000/QALY).
The results of this study are broadly comparable with
those of Purshouse et al. [11] who modelled similar pro-
grammes in England. Both studies show programmes of
screening and brief interventions to be cost-effective, or
even cost-saving, in a primary health care context. Theydelivery costs and effectiveness estimates: ICERs versus a
Higher GP costs
(€1.58/min)
Longer intervention
(24.9 min)
Longer intervention,
higher GP costs &
cheaper hospital costs
€ 2000 € 3900 € 7400
€ 5900 € 8800 € 14000
€ 10900 € 15100 € 22500
€ 19400 € 26000 € 37200
Higher GP costs
(€1.58/min)
Longer intervention
(24.9 min)
Longer intervention,
higher GP costs &
cheaper hospital costs
€ 1900 € 3600 € 6700
€ 5400 € 8000 € 12600
€ 10100 € 13900 € 20600
€ 17900 € 23900 € 33900
Table 4 Model results for alternative implementation scenarios, ordered by incremental net benefit
Setting Screening tool
and threshold (M/F)
Delivery
costs (€m)
INHS savings
(€m)
Net cost to
INHS (€m)
QALY gains
('000 s)
Incremental net
benefit versus
do-nothing (€m)*
A Registration FAST 3 & AUDIT 8 254 299 −45 57 1378
B Registration FAST 3 259 297 −39 57 1381
C Registration AUDIT 8 284 321 −38 62 1520
D Registration AUDIT 8/6 316 321 −5 62 1555
E Registration AUDIT-C 5/4 & AUDIT 8 356 338 17 67 1680
Next registration (baseline) Registration AUDIT-C 5/4 411 370 41 75 1921
F Consultation FAST 3 & AUDIT 8 419 503 −84 111 2684
G Consultation FAST 3 422 505 −84 111 2694
H Consultation AUDIT 8 470 500 −30 121 3000
I Consultation AUDIT 8/6 529 544 −15 122 3030
J Consultation AUDIT-C 5/4 & AUDIT 8 595 519 76 127 3258
Next consultation (baseline) Consultation AUDIT-C 5/4 687 605 82 139 3562
*Assuming a willingness-to-pay of €25000/QALY.
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implementation costs than screening at next GP consult-
ation, as a result of screening a smaller proportion of the
population, but with reduced savings to the health ser-
vice in the longer run and smaller gains in health-related
quality of life. For a programme of screening at next
registration, delivery costs are greater in Italy as a result
of the substantially larger proportion of the population
captured (63% screened, with 32% receiving a brief inter-
vention versus 39% and 13% respectively in England). As
a result hospital costs and QALY gains are also estimated
to be greater, although the policy is estimated to be
largely cost-neutral rather than cost-saving. The results
of this analysis are also similar to those of Solberg et al.
[44] in the USA who estimated an ICER of $1755
(equivalent to €1721 in 2008 prices) and Tariq et al. [45]
in the Netherlands who estimated an ICER of €5400, al-
though these studies both use substantially different
methodologies.
The principal challenges to this analysis were those
presented by the availability of Italian data with which to
adapt the existing model. Whilst every effort was made
to obtain suitable data specific to the Italian context this
was not always possible, and a number of assumptions
had to be made regarding the similarities of the English
and Italian health care systems. Another significant limi-
tation is the lack of available evidence on the ways in
which different population subgroups respond to brief
interventions, both in terms of the immediate impact on
consumption and the duration of effect. Whilst several
studies have attempted to investigate differential effect-
iveness by age and gender, a recent review of reviews
identified that this evidence is still inconclusive [46].
There is some evidence that SBIs are less effectiveamongst young adults and older drinkers; however a re-
cent meta-analysis estimated mean consumption reduc-
tions of 11.3% and 10.6% respectively for these
populations [47], considerably above the pessimistic as-
sumption of 5.9% tested in this study. It should also be
noted that no effect is assumed for patients who have
been screened, but receive no brief intervention, al-
though a number of studies report consumption reduc-
tions in control groups under these circumstances.
Whilst this may be explained by regression to the mean
or an observer (or ‘Hawthorne’) effect, it may also be
that screening alone has some impact as a spur to re-
duce consumption [46]. Further research into heterogen-
eity of response must be considered a high priority for
decision-makers seeking to identify the populations who
would benefit most from SBIs. Such studies may also
wish to consider the probable impact that alcohol con-
sumption, socioeconomic status, ethnicity and other fac-
tors may have on GP registration, consultation and
screening rates.
When considering the results presented in this study,
thought should be given to the relationship of both the
‘do-nothing’ comparator scenario and the modelled
programme to the realities of primary care. This analysis
assumes that in the absence of an SBI programme, no
alternative alcohol-related interventions or advice are
offered and that population consumption remains un-
changed (after adjusting for changes in the age-sex dis-
tribution). Similarly the modelled programme assumes
100% of GPs participate, all eligible patients are screened
at the first opportunity and no patients are screened
more than once. At present the delivery in primary care
in Italy of either formal SBIs or informal advice aimed at
reducing patients’ drinking is likely to be infrequent and
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study. The question of cost-effectiveness for partial up-
take rates (i.e. where not every GP participates, or not
every eligible patient is screened) is an important one
for policy makers. The ODHIN project incorporates a
major pan-European trial to investigate how different
strategies (such as financial incentives or educational
programmes) can improve these uptake rates [48] and
we plan to utilise the results of this trial in the future to
investigate the cost-effectiveness of such strategies as
well as partial uptake rates. Finally, whilst the assump-
tion that no patient is screened more than once may not
hold true in practice, the published evidence on the ef-
fect of repeated brief interventions on alcohol consump-
tion is limited and it is possible that the benefits of such
repeat interventions may outweigh the additional costs
of their delivery.
In the model we assume, in the absence of any alterna-
tive evidence, linear relationship between certain vari-
ables in the model. These assumptions fall into three
main areas: the rebound of alcohol consumption follow-
ing an SBI to pre-intervention levels; the time lags be-
tween changes in alcohol consumption and changes in
risk of chronic alcohol-related harms; and the dose–re-
sponse relationships between alcohol consumption and
relative risk of acute alcohol-related harms. It is possible
that the true relationships between these variables may
be non-linear, in such a way that the non-linear reduc-
tion in effect over time post-SBI could lead a model with
linear assumptions to over-estimate the benefits of the
SBI programme. To mitigate this possibility, we have
run a highly conservative linear sensitivity analysis in
which the effect of intervention lasts only 3 years, and
demonstrated that this change does not affect the overall
conclusions of the study. The baseline time lag assump-
tion is already conservative with respect to the limited
available evidence, which suggests that the majority of
the long-term health benefits are experienced in the first
few years following a change in consumption [49]. The
baseline dose–response relationships for acute condi-
tions are also conservative from the perspective of ef-
fects on episodic heavy drinkers (who are more likely to
be given a brief intervention) since candidate alternative
risk functions for these conditions (e.g. quadratic or ex-
ponential forms) would have steeper gradients at higher
levels of consumption, leading to greater falls in risk and
therefore greater reductions in harm than in the linear
case, for any given reduction in consumption.
Conclusions
This study is the first to evaluate the cost-effectiveness
of a programme of screening and brief interventions
in primary care in Italy. In common with other studies
internationally the results demonstrate that suchprogrammes are highly likely to be cost-effective, even
under the most pessimistic assumptions. In the present
financial climate these results provide a strong recom-
mendation for the regional Italian bodies to increase
their use of SBIs as an effective tool for improving public
health and reducing the burden on the INHS. However,
policy makers should be mindful of the differing cost-
implications of alternative programmes of implementa-
tion. Whilst screening at next GP consultation brings
the greatest health benefits and affects the largest num-
ber of people, it also carries a heavily front-loaded re-
source profile, whereas implementing a programme of
screening at next GP registration offers a much more
even spread of resourcing over the duration of the
programme. These differences may have a major effect
on the acceptability of different SBI programme options
to policy makers attempting to balance limited health
care budgets.Additional file
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